Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Revance Therapeutics, Inc.

RVNC

New York, New York--(Newsfile Corp. - October 13, 2021) - Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC) concerning possible violations of federal securities laws.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/99527_2d8211ede4445914_001full_200.jpg

On October 12, 2021, Revance revealed the U.S. Food and Drug Administration ("FDA") posted Form 483 to its website citing issues found during the inspection of a Revance Therapeutics, Inc. facility in July 2021. Among other deficiencies, the FDA noted a working cell bank as a cause of rejected GMP lots of a product, discrepancies between the manufacturing process compared to that proposed for licensure, and said the Company's quality unit "lacks the responsibility and authority for the control, review, and approval of outsourced activities…".

On this news, shares of Revance Therapeutics fell over 25% in intraday trading on October 12, 2021. To obtain additional information, go to:

https://www.zlk.com/pslra-1/revance-therapeutics-inc-information-request-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

WHY LEVI & KORSINSKY: Levi & Korsinsky have a proven track record of winning cases worth hundreds of millions of dollars for shareholders over a 20-year period. We represent and fight for shareholders who have been wronged by corporations.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington, D.C. The Firm's Founding Partners, Joseph Levi and Eduard Korsinsky, have been representing shareholders and institutional clients for almost 20 years and have achieved remarkable results for clients in the U.S. and internationally. The firm, with more than 80 employees, is committed to fostering, cultivating and preserving a culture of diversity, equity and inclusion for employees and those that we represent. Our attorneys have extensive expertise representing investors in securities litigation with a track record of recovering hundreds of millions of dollars in cases. Levi & Korsinsky was ranked in Institutional Shareholder Services' ("ISS") SCAS Top 50 Report for 7 years in a row as a top securities litigation firm in the United States. The SCAS Top 50 Report identifies the top plaintiffs' securities law firms in the country, and year after year, ISS has recognized Levi & Korsinsky as a leading firm in the area of securities class action litigation.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/99527